552 related articles for article (PubMed ID: 10745621)
21. Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.
Chene A; Donati D; Orem J; Mbidde ER; Kironde F; Wahlgren M; Bejarano MT
Semin Cancer Biol; 2009 Dec; 19(6):411-20. PubMed ID: 19897039
[TBL] [Abstract][Full Text] [Related]
22. [Malignant lymphoma and EBV].
Ohshima K; Kikuchi M
Rinsho Byori; 1996 Jan; 44(1):24-31. PubMed ID: 8691636
[TBL] [Abstract][Full Text] [Related]
23. [Biology of the Epstein-Barr virus].
Morand P; Seigneurin JM
Ann Biol Clin (Paris); 1989; 47(7):421-7. PubMed ID: 2554764
[TBL] [Abstract][Full Text] [Related]
24. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors.
Eminger LA; Hall LD; Hesterman KS; Heymann WR
J Am Acad Dermatol; 2015 Jan; 72(1):21-34; quiz 35-6. PubMed ID: 25497918
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative disease/lymphoma: clinicopathologic, serologic, and molecular analysis.
Mitarnun W; Suwiwat S; Pradutkanchana J; Saechan V; Ishida T; Takao S; Mori A
Am J Hematol; 2002 May; 70(1):31-8. PubMed ID: 11994979
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma.
Shah KM; Young LS
Clin Microbiol Infect; 2009 Nov; 15(11):982-8. PubMed ID: 19874382
[TBL] [Abstract][Full Text] [Related]
28. [Epstein-Barr virus infections. New pathogenic and clinical aspects].
Wilmes E; Wolf H
Laryngorhinootologie; 1989 Jan; 68(1):36-43. PubMed ID: 2536874
[TBL] [Abstract][Full Text] [Related]
29. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist.
Delecluse HJ; Feederle R; O'Sullivan B; Taniere P
J Clin Pathol; 2007 Dec; 60(12):1358-64. PubMed ID: 17873116
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr viral load measurement as a marker of EBV-related disease.
Fan H; Gulley ML
Mol Diagn; 2001 Dec; 6(4):279-89. PubMed ID: 11774193
[TBL] [Abstract][Full Text] [Related]
31. [Recent aspects of Epstein-Barr virus infections].
Hasler F
Schweiz Med Wochenschr; 1984 Apr; 114(15):520-3. PubMed ID: 6328644
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus-Epstein-Barr virus interaction in patients with AIDS.
Challine D; Buisson M; Cadilhac M; Germanidis G; Joab I; Eliaszewicz M; Caumes E; Flahault A; Fillet AM; Pawlotsky JM; Seigneurin JM
J Med Virol; 2002 Aug; 67(4):510-5. PubMed ID: 12115996
[TBL] [Abstract][Full Text] [Related]
33. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders.
Iwatsuki K; Satoh M; Yamamoto T; Oono T; Morizane S; Ohtsuka M; Xu ZG; Suzuki D; Tsuji K
Arch Dermatol; 2006 May; 142(5):587-95. PubMed ID: 16702496
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus: 40 years on.
Young LS; Rickinson AB
Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
[TBL] [Abstract][Full Text] [Related]
35. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
[TBL] [Abstract][Full Text] [Related]
36. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients.
Okano M; Gross TG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):403-13. PubMed ID: 17547505
[TBL] [Abstract][Full Text] [Related]
37. [X-chromosomal recessively inherited lymphoproliferative syndrome. An analysis of EBV-induced immune deficiency].
Kammermeier-Schmidt U; Weiss M; Belohradsky BH
Monatsschr Kinderheilkd; 1993 Mar; 141(3):201-6. PubMed ID: 8386321
[TBL] [Abstract][Full Text] [Related]
38. [Role of Epstein-Barr Virus in lymphoproliferative disorders].
Raphael M
Bull Acad Natl Med; 1997; 181(6):999-1007; discussion 1007-8. PubMed ID: 9453845
[TBL] [Abstract][Full Text] [Related]
39. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
40. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.
Ohshima K; Kimura H; Yoshino T; Kim CW; Ko YH; Lee SS; Peh SC; Chan JK;
Pathol Int; 2008 Apr; 58(4):209-17. PubMed ID: 18324913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
